Leveraging an immune cell signature to improve the survival and immunotherapy response of lung adenocarcinoma

Zhang, Jiacheng; Kuang, Tianrui; Dong, Keshuai; Yu, Jia; Wang, Weixing

doi:10.7150/jca.90515



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2024; 15(3):747-763. doi:10.7150/jca.90515 This issue Cite

Research Paper

Leveraging an immune cell signature to improve the survival and immunotherapy response of lung adenocarcinoma

Jiacheng Zhang^1,2#, Tianrui Kuang^1,2#, Keshuai Dong¹, Jia Yu^1✉, Weixing Wang^3✉

1. Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, People's Republic of China.
2. Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, People's Republic of China.
3. Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, People's Republic of China.
#Authors contributed equally to this work.

Citation:

Zhang J, Kuang T, Dong K, Yu J, Wang W. Leveraging an immune cell signature to improve the survival and immunotherapy response of lung adenocarcinoma. J Cancer 2024; 15(3):747-763. doi:10.7150/jca.90515. https://www.jcancer.org/v15p0747.htm

Other styles

Abstract

Background: Immune cells play a critical role in the prognosis of cancer. However, the function of different immune cell types in lung adenocarcinoma (LUAD) and the development of a prognostic signature based on immune cell types have not been comprehensively investigated.

Methods: We collected and included a total of 2499 LUAD patients and performed calculations to determine the penetration level of 24 immune cells. This examination was conducted using the macro-gene-based approach provided by ImmuCellAI. We performed a meta-analysis using Lasso-Cox analysis to establish the immune cell pair score (ICPS). We conducted a survival analysis to measure differences in survival across ICPS-risk groups. Wilcox test was used to measure the difference in expression level. Spearman correlation analysis was used for the relevance assessment.

Results: We collected a total of 24 immune cell types to construct cell pairs. Utilizing 17 immune cell pairs, we constructed and validated the ICPS, which plays a critical role in stratifying survival and dynamically monitoring the effectiveness of immunotherapy. Additionally, we identified several candidate drugs that target ICPS.

Conclusions: The ICPS shows promise as a valuable tool for identifying suitable candidates for immunotherapy among patients. Our comprehensive assessment of immune cell interactions in LUAD contributes to a deeper understanding of infiltration patterns and functions, thereby guiding the development of more efficacious immunotherapy strategies.

Keywords: immune cell, immunotherapy, lung adenocarcinoma, prognosis, tumor microenvironment

Citation styles

APA

Zhang, J., Kuang, T., Dong, K., Yu, J., Wang, W. (2024). Leveraging an immune cell signature to improve the survival and immunotherapy response of lung adenocarcinoma. Journal of Cancer, 15(3), 747-763. https://doi.org/10.7150/jca.90515.

ACS

Zhang, J.; Kuang, T.; Dong, K.; Yu, J.; Wang, W. Leveraging an immune cell signature to improve the survival and immunotherapy response of lung adenocarcinoma. J. Cancer 2024, 15 (3), 747-763. DOI: 10.7150/jca.90515.

NLM

CSE

Zhang J, Kuang T, Dong K, Yu J, Wang W. 2024. Leveraging an immune cell signature to improve the survival and immunotherapy response of lung adenocarcinoma. J Cancer. 15(3):747-763.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.